Evofem and Windtree mutually terminate PHEXXI supply agreement, no fees

Evofem Biosciences, Inc.

License and Supply Agreement for PHEXXI manufacturing terminated March 13, 2026, by mutual consent.
Windtree had not established required manufacturing capabilities; no termination fees payable.
Windtree must return all Evofem confidential information and property; survival provisions remain.
Agreement originally entered March 20, 2025, and amended March 28, 2025, now terminated.

item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evofem Biosciences, Inc. terminated Termination Agreement with Windtree Therapeutics, Inc. (effective 2026-03-13).

Action: termination
Agreement: supply
Counterparty: Windtree Therapeutics, Inc.
Effective: 2026-03-13

Exact text from the filing

the Company and Windtree entered into a Termination Agreement (the “Termination Agreement”) pursuant to which the parties mutually consented to the termination of the Agreement, effective as of such date.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-011613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.